Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS

Equities research analysts expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce earnings of $0.11 per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming in at $0.39 and the lowest estimate coming in at ($0.06). Neurocrine Biosciences posted earnings per share of ($0.51) during the same quarter last year, which suggests a positive year-over-year growth rate of 121.6%. The business is expected to announce its next quarterly earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.31). For the next year, analysts forecast that the company will report earnings of $0.05 per share, with EPS estimates ranging from ($1.36) to $1.30. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same quarter in the previous year, the firm posted ($0.43) earnings per share.

Several analysts have commented on the stock. Jefferies Group lifted their price objective on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Oppenheimer lifted their target price on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Citigroup reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $86.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $82.31.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $2.12 during midday trading on Friday, reaching $80.68. 1,027,685 shares of the company’s stock traded hands, compared to its average volume of 806,461. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences has a twelve month low of $38.43 and a twelve month high of $83.84. The firm has a market cap of $6,952.01, a PE ratio of -36.34, a price-to-earnings-growth ratio of 73.48 and a beta of 0.35.

In related news, insider Kyle Gano sold 24,818 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now owns 84,596 shares of the company’s stock, valued at approximately $6,010,545.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Darin Lippoldt sold 9,900 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. In the last three months, insiders sold 121,780 shares of company stock valued at $9,012,926. 4.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Trust Advisors LP increased its holdings in Neurocrine Biosciences by 29.0% in the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after acquiring an additional 176,136 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Neurocrine Biosciences by 2.6% in the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares in the last quarter. Davidson Kempner Capital Management LP purchased a new stake in Neurocrine Biosciences in the 2nd quarter worth $3,639,000. State Street Corp increased its holdings in Neurocrine Biosciences by 5.1% in the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock worth $124,666,000 after acquiring an additional 131,141 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in Neurocrine Biosciences by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 179,300 shares of the company’s stock worth $8,248,000 after acquiring an additional 3,900 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/analysts-anticipate-neurocrine-biosciences-inc-nbix-to-announce-0-11-eps.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply